Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 2
-10%
portes grátis
Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 2
Diagnosis, Therapeutic Targets, and Molecular Mechanisms
Vadde, Ramakrishna; Nagaraju, Ganji Purnachandra
Elsevier Science & Technology
04/2022
398
Dura
Inglês
9780323988070
15 a 20 dias
1000
Descrição não disponível.
1. Hepatocellular carcinoma diagnosis2. Computational analysis of prognosisrelated genes in liver cancer3. Computational approaches to identify biomarkers, enzymes, and pathways of hepatocellular carcinoma4. Ribonucleic acid sequence analysis in deciphering hepatocellular carcinoma5. Hepatocarcinogenesis and the role of next-generation sequencing in liver cancer6. Liver cancer: the tumor microenvironment and associated pathways7. Metabolic pathway-based target therapy to hepatocellular carcinoma: a computational approach8. Targeting ion channels in hepatic cancer9. Tyrosine kinases: their role in hepatocellular carcinoma10. Role of transcription factors in hepatocellular carcinoma11. Modulatory act of diverse transcriptional factors in liver carcinoma12. Association of specificity protein 1 with hepatocellular carcinoma13. Promising biomarkers for liver cancer14. Molecular signaling and its role in drug resistance in hepatocellular carcinomas15. Multidrug resistance, a major obstacle in hepatocellular carcinoma treatment: challenges and future perspectives16. Proliferative signaling pathways in hepatocellular carcinoma17. Targeting angiogenesis in hepatocellular carcinoma18. Conventional and novel biomarkers for the diagnosis and prognosis of liver cancer19. Updates on the staging and treatment of hepatocellular carcinoma20. ROS-mediated pathways: potential role in hepatocellular carcinoma biology and therapy21. Dysregulated cell-signaling pathways in hepatocellular carcinoma: causes and therapeutic options22. LKB1/STK11-mediated signal transduction in hepatocellular carcinoma
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
?AFP; AP-1; Adenosine monophosphate kinase; Angiogenesis; Antiangiogenic treatment; BCLC staging system; Bioinformatics analysis; Biomarker; Biomarkers; Cell signaling; Chemoresistance molecularly targeted agents; Des-gamma-carboxyprothrombin; Des-?-carboxyprothrombin; Diagnosis; Dickkopf-1; Drug resistance; E2F; ECM; EGFR; EMT; Enzymes and pathways; Epithelial mesenchymal transition; FOXM1; Gene ontology; Gene transcription; Genetic profiling; Glucose; Glycocholate; Golgi protein 73; HCC; HER2; HGF/MET; HIFs; Heat shock protein; Hepatitis B and C virus; Hepatocarcinogenesis; Hepatocellular cancer; Hepatocellular carcinoma; Hepatocellular carcinoma (HCC); Heterogeneity; Heteromeric complexes; Hippo; Inhibitors; Insulin; Invasiveness; Ion channels; JAK/STAT; Liver cancer; Liver cirrhosis; Liver kinase B1; Liver neoplasms; Liver transplantation; Long noncoding RNAs; MAP kinase; MTOR; Malignant liver cancer; Mathematical models; Metabolism; Metastasis; MicroRNA; Migration; Molecular heterogeneity; Multidrug resistance; NF-?B; Next-generation sequence; Next-generation sequencing (NGS); Nodal; Noncoding RNA; Notch; Nuclear receptor; Osteopontin; PI3K-AKT; PIVKA-II; Pathophysiology; Pathways; Perfusion CT; Perfusion MRI; Phenylalanyl-tryptophan; Phosphatidylinositol proteoglycan; Phosphorylation; Potential markers; Precision medicine; Prognostic factors; Proliferative signaling; Protein induced by vitamin K deficiency; RNA sequence; Radiofrequency ablation; Reactive oxygen species; Resistance; Rho-A; Risk factors; Sensitivity; Serine threonine kinase 11; Signaling; Signaling pathway; Signaling pathways; Sorafenib; Specificity; Specificity protein 1; Steatosis
1. Hepatocellular carcinoma diagnosis2. Computational analysis of prognosisrelated genes in liver cancer3. Computational approaches to identify biomarkers, enzymes, and pathways of hepatocellular carcinoma4. Ribonucleic acid sequence analysis in deciphering hepatocellular carcinoma5. Hepatocarcinogenesis and the role of next-generation sequencing in liver cancer6. Liver cancer: the tumor microenvironment and associated pathways7. Metabolic pathway-based target therapy to hepatocellular carcinoma: a computational approach8. Targeting ion channels in hepatic cancer9. Tyrosine kinases: their role in hepatocellular carcinoma10. Role of transcription factors in hepatocellular carcinoma11. Modulatory act of diverse transcriptional factors in liver carcinoma12. Association of specificity protein 1 with hepatocellular carcinoma13. Promising biomarkers for liver cancer14. Molecular signaling and its role in drug resistance in hepatocellular carcinomas15. Multidrug resistance, a major obstacle in hepatocellular carcinoma treatment: challenges and future perspectives16. Proliferative signaling pathways in hepatocellular carcinoma17. Targeting angiogenesis in hepatocellular carcinoma18. Conventional and novel biomarkers for the diagnosis and prognosis of liver cancer19. Updates on the staging and treatment of hepatocellular carcinoma20. ROS-mediated pathways: potential role in hepatocellular carcinoma biology and therapy21. Dysregulated cell-signaling pathways in hepatocellular carcinoma: causes and therapeutic options22. LKB1/STK11-mediated signal transduction in hepatocellular carcinoma
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
?AFP; AP-1; Adenosine monophosphate kinase; Angiogenesis; Antiangiogenic treatment; BCLC staging system; Bioinformatics analysis; Biomarker; Biomarkers; Cell signaling; Chemoresistance molecularly targeted agents; Des-gamma-carboxyprothrombin; Des-?-carboxyprothrombin; Diagnosis; Dickkopf-1; Drug resistance; E2F; ECM; EGFR; EMT; Enzymes and pathways; Epithelial mesenchymal transition; FOXM1; Gene ontology; Gene transcription; Genetic profiling; Glucose; Glycocholate; Golgi protein 73; HCC; HER2; HGF/MET; HIFs; Heat shock protein; Hepatitis B and C virus; Hepatocarcinogenesis; Hepatocellular cancer; Hepatocellular carcinoma; Hepatocellular carcinoma (HCC); Heterogeneity; Heteromeric complexes; Hippo; Inhibitors; Insulin; Invasiveness; Ion channels; JAK/STAT; Liver cancer; Liver cirrhosis; Liver kinase B1; Liver neoplasms; Liver transplantation; Long noncoding RNAs; MAP kinase; MTOR; Malignant liver cancer; Mathematical models; Metabolism; Metastasis; MicroRNA; Migration; Molecular heterogeneity; Multidrug resistance; NF-?B; Next-generation sequence; Next-generation sequencing (NGS); Nodal; Noncoding RNA; Notch; Nuclear receptor; Osteopontin; PI3K-AKT; PIVKA-II; Pathophysiology; Pathways; Perfusion CT; Perfusion MRI; Phenylalanyl-tryptophan; Phosphatidylinositol proteoglycan; Phosphorylation; Potential markers; Precision medicine; Prognostic factors; Proliferative signaling; Protein induced by vitamin K deficiency; RNA sequence; Radiofrequency ablation; Reactive oxygen species; Resistance; Rho-A; Risk factors; Sensitivity; Serine threonine kinase 11; Signaling; Signaling pathway; Signaling pathways; Sorafenib; Specificity; Specificity protein 1; Steatosis
